Luca Issi
Stock Analyst at RBC Capital
(1.33)
# 3,300
Out of 4,749 analysts
178
Total ratings
36.36%
Success rate
-14.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $26 | $30.32 | -14.23% | 4 | Jan 29, 2025 | |
| QURE uniQure | Reiterates: Outperform | $24 | $15.86 | +51.32% | 6 | Jan 21, 2025 | |
| SLB Schlumberger | Reiterates: Outperform | $57 | $40.95 | +39.19% | 1 | Jan 21, 2025 | |
| RGNX REGENXBIO | Reiterates: Outperform | $30 | $8.00 | +274.85% | 9 | Jan 21, 2025 | |
| LXEO Lexeo Therapeutics | Reiterates: Outperform | $24 | $5.34 | +349.44% | 4 | Jan 21, 2025 | |
| RNA Avidity Biosciences | Reiterates: Outperform | $67 | $32.49 | +106.21% | 2 | Jan 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $300 | $276.55 | +8.48% | 24 | Jan 21, 2025 | |
| IONS Ionis Pharmaceuticals | Reiterates: Outperform | $70 | $33.00 | +112.12% | 7 | Jan 15, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $45 | $14.19 | +217.12% | 2 | Jan 14, 2025 | |
| EDIT Editas Medicine | Maintains: Sector Perform | $5 → $4 | $1.41 | +184.70% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $7.93 | +908.83% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $11 | $6.53 | +68.45% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $39 | $5.54 | +603.97% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $43.56 | +76.76% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $7.45 | +128.34% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $53 | $41.95 | +26.34% | 12 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $27 → $24 | $27.44 | -12.52% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $10 | $4.44 | +125.23% | 6 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $63.97 | +25.06% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $12.11 | +23.86% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $105 | $35.61 | +194.86% | 6 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $20.12 | +108.75% | 7 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $75 | $41.17 | +82.17% | 12 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $10.37 | +420.98% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.35 | +937.11% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.98 | +406.33% | 7 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $1.22 | +64.61% | 5 | Mar 14, 2024 |
Apellis Pharmaceuticals
Jan 29, 2025
Maintains: Sector Perform
Price Target: $26
Current: $30.32
Upside: -14.23%
uniQure
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $15.86
Upside: +51.32%
Schlumberger
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $40.95
Upside: +39.19%
REGENXBIO
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $8.00
Upside: +274.85%
Lexeo Therapeutics
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $5.34
Upside: +349.44%
Avidity Biosciences
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $32.49
Upside: +106.21%
Alnylam Pharmaceuticals
Jan 21, 2025
Reiterates: Outperform
Price Target: $300
Current: $276.55
Upside: +8.48%
Ionis Pharmaceuticals
Jan 15, 2025
Reiterates: Outperform
Price Target: $70
Current: $33.00
Upside: +112.12%
Dyne Therapeutics
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $14.19
Upside: +217.12%
Editas Medicine
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.41
Upside: +184.70%
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $7.93
Upside: +908.83%
Nov 14, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $6.53
Upside: +68.45%
Nov 14, 2024
Maintains: Outperform
Price Target: $40 → $39
Current: $5.54
Upside: +603.97%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $43.56
Upside: +76.76%
Nov 6, 2024
Maintains: Outperform
Price Target: $20 → $17
Current: $7.45
Upside: +128.34%
Nov 6, 2024
Reiterates: Sector Perform
Price Target: $53
Current: $41.95
Upside: +26.34%
Nov 6, 2024
Maintains: Sector Perform
Price Target: $27 → $24
Current: $27.44
Upside: -12.52%
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $4.44
Upside: +125.23%
Oct 30, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $63.97
Upside: +25.06%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $12.11
Upside: +23.86%
Oct 21, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $35.61
Upside: +194.86%
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $20.12
Upside: +108.75%
Sep 19, 2024
Reiterates: Sector Perform
Price Target: $75
Current: $41.17
Upside: +82.17%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $10.37
Upside: +420.98%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.35
Upside: +937.11%
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.98
Upside: +406.33%
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $1.22
Upside: +64.61%